Bioventus Inc. · NASDAQ:BVS
Bioventus — 43rd Annual J.P. Morgan Healthcare Conference 2025
14 slides from Bioventus's conference presentation, January 2025
Slide 1: Bioventus: Helping Patients Recover and Live Life to the Fullest
Bioventus Helping Patients Recover and Live Life to the Fullest 43rd Annual J.P. Morgan Healthcare Conference Rob Claypoole, President and CEO
Slide 2: Forward Looking Statements
Forward Looking Statements Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this presentation t
Slide 3: Bioventus: A Compelling Investment Opportunity
BIOVENTUS: A Compelling Investment Opportunity Strong $6.4 Billion Significant Market Leadership Market Opportunity Value Creation * Diversified Portfolio in Large and $555M 1 Pain Treatments LTM Global Proforma Revenue Growing Markets Surgical Solutions Accelerating Revenue Growth Pain Treatments C
Slide 4: Delivering Strong 2024 Financial Performance and Improved Execution
Delivering Strong 2024 Financial Performance and Improved Execution Organic Growth $ millions Adjusted EBITDA 13.2% 105.5 88.9 66.3 3.6% 0.7% 2022 2023 2024 2022 2023 2024 2022 – 2023 growth as shown in year-end earnings release 2024 organic growth reflects mid-point of financial guidance provided o
Slide 5: Driving Above Market Growth Across Diverse Portfolio
Driving Above Market Growth Across Diverse Portfolio Market Near-Term Long-Term Key Growth Growth Growth Growth Drivers Highest Market Development Growth MSD DD DD Share Gains Ultrasonics Weighted Average BGS Market Share Gains Q3 2024 Leaders LSD+ HSD+ MSD+ Renewed Focus on Business YTD HA Revenue*
Slide 6: Establishing New Standard of Care with Differentiated Ultrasonics Technology
Highest Growth Market Leader Emerging Growth Establishing New Standard of Care with Differentiated Ultrasonics Technology Background Growth Catalysts Go Forward Strategy ➢ TAM: $0.9 Billion ➢ Differentiated technology ➢ Strengthen value proposition ➢ BVS Growth Expectation: DD ➢ R&D expertise ➢ Driv
Slide 7: Positioning Bone Graft Substitutes as an Alternative Within the Premium Segment
Highest Growth Market Leader Emerging Growth Positioning Bone Graft Substitutes as an Alternative Within the Premium Segment Background Growth Catalysts Go Forward Strategy ➢ TAM: $1.0 Billion ➢ OSTEOAMP economic value ➢ Focus on premium biologic proposition space ➢ BVS Growth Expectation: DD ➢ Mark
Slide 8: Market Leading HA Therapy for KOA Continues to Gain Market Share
Highest Growth Market MarketLeader Leader Emerging Growth Market Leading HA Therapy for KOA Continues to Gain Market Share Background Growth Catalysts Go Forward Strategy ➢ TAM: 2.1 Billion ➢ Durolane clinical differentiation ➢ Invest in medical education ➢ BVS Growth Expectation: HSD ➢ Dedicated sa
Slide 9: Exogen Continues to Drive Improved Growth from Increased Prioritization
Highest Growth Market MarketLeader Leader Emerging Growth Exogen Continues to Drive Improved Growth from Increased Prioritization and Enhanced Execution Background Growth Catalysts Go Forward Strategy ➢ TAM: $0.4 Billion ➢ Maintain renewed focus ➢ Increase medical education ➢ BVS Growth Expectation:
Slide 10: Break-through Innovation in Peripheral Nerve Stimulation
Highest Growth Market Leader Emerging Growth Break-through Innovation in Peripheral Nerve Stimulation Will Contribute to Above Market Growth for Bioventus Background Growth Catalysts Go Forward Strategy ➢ TAM: $2+ Billion ➢ Gain FDA clearance in 2025 ➢ Prepare for market launch ➢ BVS Growth Expectat
Slide 11: Peer Leading Gross Margin Provides Ability to Re-invest and Accelerate EBITDA Margin
Peer Leading Gross Margin Combined with Above Market Growth Provides Ability to Re-invest and Accelerate EBITDA Margin Peer-leading, consistent mid-70’s gross Funding for Growth Investments margin • Expand sales force • Enhance market awareness + • Educate surgeons Consistent EBITDA Margin Expansion
Slide 12: Accelerating Cash Flow and Enhancing Liquidity in 2025
Accelerating Cash Flow and Enhancing Liquidity in 2025 Higher EBITDA Free Cash Flow Growth: 2X 2024 FCF Working Capital Lower Cash Flow Yield*: 60%+ Interest Efficiency Expense 2025 Net Leverage*: <3.0x Decrease in 2H 2025 One-Time Cash Costs 2025 J.P. Morgan Healthcare Conference * Free Cash Flow y
Slide 13: Enhancing Shareholder Value with Improved Execution and Financial Discipline
Enhancing Shareholder Value with Improved Execution and Financial Discipline • Improving Focus and Execution • Accelerating Growth with a Diversified Portfolio of Short and Long-Term Drivers • Enhancing Flexibility to Invest While Continuing to Drive Operating Margin Improvement • Doubling Cash Flow
Slide 14: Thank You
a Thank You @ bioventus’
Bioventus — 43rd Annual J.P. Morgan Healthcare Conference 2025 on 6ix